Suppr超能文献

不同抗雄激素药物在中国跨性别女性中的疗效及用户满意度

The efficacy of and user satisfaction with different antiandrogens in Chinese transgender women.

作者信息

Yang Wenhui, Hong Tianpei, Chang Xu, Han Meng, Gao Hongwei, Pan Bailin, Zhao Zhenmin, Liu Ye

机构信息

Department of Plastic Surgery, Peking University Third Hospital, Beijing, China.

Department of Endocrinology and Metabolism, Peking University Third Hospital, Beijing, China.

出版信息

Int J Transgend Health. 2024 Mar 14;25(3):471-482. doi: 10.1080/26895269.2024.2323514. eCollection 2024.

Abstract

OBJECTIVE

Cyproterone acetate (CPA) and spironolactone (SPL) are different antiandrogens in gender-affirming hormone therapy (GAHT) for transgender women. Few studies have evaluated their efficacy and user satisfaction, especially among East Asians. This study aimed to evaluate these aspects in Chinese transgender women.

METHODS

Data were collected retrospectively from transgender women visiting the Peking University Third Hospital from 2012 to 2021. From 639 people identified as transgender women, 151 of them (80 using CPA and 71 using SPL, 16 to 40-year-old) under stable GAHT ≥6 months were enrolled. Total testosterone levels and visual analogue scale (VAS)-based satisfaction scores were evaluated.

RESULTS

No difference was observed in age between the CPA and SPL groups (median [IQR], 22 [20-24] years and 23 [20-26] years, respectively). The duration of GAHT was longer in CPA group than in SPL group (18 [10-32] months vs. 12 [8-21] months,  = 0.009). Total testosterone levels were significantly lower with CPA treatment (25 mg/d) than with SPL treatment (100 mg/d) (median [IQR]: 0.7 [0.7-2.1] nmol/L vs. 13.0 [6.0-17.8] nmol/L,  < 0.001). The proportion of total testosterone levels reaching the recommended range was significantly higher in CPA group than in SPL group (75.0% vs. 11.3%,  < 0.001). VAS-based satisfaction scores for erection decreased and figure feminization were higher in CPA group than in SPL group, which remained unchanged after adjusting for age, treatment duration, estradiol dose, and comorbid mental disorders ( < 0.05). The prolactin levels were higher in CPA group than in SPL group (18.9 [11.8-28.1] ng/ml vs. 11.8 [7.9-18.4] ng/ml,  < 0.001). No severe safety events were reported in both groups.

CONCLUSION

In Chinese transgender women, CPA was more effective than SPL in lowering testosterone levels. Additionally, VAS scores indicated greater satisfaction with erection decreased and figure feminization using CPA compared to SPL.

摘要

目的

醋酸环丙孕酮(CPA)和螺内酯(SPL)是用于跨性别女性性别确认激素治疗(GAHT)的不同抗雄激素药物。很少有研究评估它们的疗效和使用者满意度,尤其是在东亚人群中。本研究旨在评估中国跨性别女性在这些方面的情况。

方法

回顾性收集2012年至2021年就诊于北京大学第三医院的跨性别女性的数据。在639名被认定为跨性别女性的人中,纳入了151名(80人使用CPA,71人使用SPL,年龄在16至40岁之间)接受稳定GAHT≥6个月的患者。评估总睾酮水平和基于视觉模拟量表(VAS)的满意度评分。

结果

CPA组和SPL组的年龄无差异(中位数[四分位间距],分别为22[20 - 24]岁和23[20 - 26]岁)。CPA组的GAHT持续时间比SPL组长(18[10 - 32]个月对12[8 - 21]个月,P = 0.009)。CPA治疗(25mg/d)后的总睾酮水平显著低于SPL治疗(100mg/d)(中位数[四分位间距]:0.7[0.7 - 2.1]nmol/L对13.0[6.0 - 17.8]nmol/L,P < 0.001)。CPA组总睾酮水平达到推荐范围的比例显著高于SPL组(75.0%对11.3%,P < 0.001)。CPA组基于VAS的勃起功能减退和身材女性化满意度评分高于SPL组,在调整年龄、治疗持续时间、雌二醇剂量和合并精神障碍后仍保持不变(P < 0.05)。CPA组的催乳素水平高于SPL组(18.9[11.8 - 28.1]ng/ml对11.8[7.9 - 18.4]ng/ml,P < 0.001)。两组均未报告严重安全事件。

结论

在中国跨性别女性中,CPA在降低睾酮水平方面比SPL更有效。此外,VAS评分表明,与SPL相比,使用CPA对勃起功能减退和身材女性化的满意度更高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a98a/11268237/599f2ebbb0fb/WIJT_A_2323514_F0001_B.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验